Inclusion Criteria:
  -  outpatients 2 to 6 years of age;
  -  males and females who are physically healthy;
  -  diagnosis of autism spectrum disorder based on clinical evaluation and DSM-5 criteria, and confirmed using the Autism Diagnostic Interview-Revised, and the Autism Diagnostic Observation Schedule;
  -  care provider who could reliably bring subject to clinic visits, could provide trustworthy ratings, and interacted with subject on a regular basis;
  -  ability of subject to swallow the compound;
  -  stable concomitant medications for at least 2 weeks (4 weeks if patient took fluoxetine);
  -  no planned changes in psychosocial interventions during the open-label trial.
Exclusion Criteria:
  -  DSM-5 diagnosis of schizophrenia, schizoaffective disorder, or psychotic disorder not otherwise specified;
  -  prior adequate trial of Esomeprazole;
  -  active medical problems such as unstable seizures, or significant physical illness (e.g., serious liver or renal pathology).